Table 2

 Muscle force and exercise capacity in patients with sarcoidosis and healthy subjects

SarcoidosisHealthy subjectsDifferences between means (95% CI)p value
Values are expressed as mean (SD) and as the differences between means (with 95% CI). Pimax, maximal inspiratory pressure; Pemax, maximal expiratory pressure; HGF, handgrip force; kgF, kilogram force; QPT, quadriceps peak torque; Nm, Newton-meter; 6MWD, distance walked in 6 minutes; Vo2, oxygen uptake; HR, heart rate; % HRmax pred, percentage of maximal heart rate predicted; Ve, ventilation; MVV, maximum voluntary ventilation.
Muscle force
    Pimax (cm H2O)−89 (31)−115 (33)−26 (−45 to −5)0.01
    Pimax (% predicted)79 (21)104 (28)25 (10 to 40)0.002
    Pemax (cm H2O)157 (53)205 (53)49 (16 to 81)0.004
    Pemax (% predicted)84 (20)112 (19)28 (16 to 40)0.0001
    HGF (kgF)38 (13)45 (13)7 (−1 to 16)0.07
    HGF (% predicted)87 (22)104 (16)17 (5 to 28)0.007
    QPT (Nm)142 (62)187 (56)45 (9 to 81)0.02
    QPT (% predicted)67 (22)95 (16)29 (17 to 41)0.0001
Functional exercise test
    6MWD (m)605 (131)788 (106)183 (109 to 256)0.0001
    6MWD (% predicted)79 (13)102 (11)23 (16 to 31)0.0001
    Dyspnoea 6MWD (points)3.7 (1.8)1.9 (1.2)−1.8 (−2.7 to −0.8)0.0006
    Fatigue 6MWD (points)4.6 (2.5)3.6 (1.7)−0.9 (−2.2 to 0.4)0.18
Peak exercise test
    Peak load (watt)165 (54)230 (72)65 (26 to 104)0.002
    Peak load (% predicted)84 (17)123 (22)40 (28 to 52)0.0001
    Peak Vo2 (ml/kg/min)25 (9)36 (10)11 (5 to 17)0.001
    Peak Vo2 (% predicted)85 (24)109 (15)24 (12 to 37)0.0003
    Peak HR (% HRmax pred)95 (9)101 (6)6 (1 to 11)0.02
    Peak Ve (% MVV)74 (17)71 (12)−3 (−12 to 6)0.53
    Lactate (mmol/l)9.8 (2.9)11.7 (3.1)1.9 (−0.2 to 4.0)0.08
    Dyspnoea cycle (points)5.9 (1.9)4.9 (2.0)−1.0 (−2.2 to 0.3)0.14
    Fatigue cycle (points)7.4 (1.9)6.3 (1.6)−1.1 (−2.2 to 0.0)0.05